WHC is still in active development. Read this to understand our approach.
depiction of UQCNKQCJZOAFTQ-UHFFFAOYSA-N.svg
tripsit

oxymorphone

Verificar en tripsit

psychonaut

Oxymorphone

Verificar en psychonaut

isomerdesign

Oxymorphone

Verificar en isomerdesign

pubchem

Oxymorphone

Verificar en pubchem

druglab

Oxymorphone

Verificar en druglab

drugmap

Oxymorphone

Verificar en drugmap

wiki

Oxymorphone

Verificar en wiki

Data

InChI: InChI=1S/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3

Sinónimos: Oxymorphone (abuse-resistant, pain), Pain Therapeutics/ King Pharmaceuticals,76-41-5,UNII-9VXA968E0C,BDBM50001707,10,17-dihydroxy-4-methyl-(13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one(oxymorphone),EN3202,10,17-dihydroxy-4-methyl-(13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one,EINECS 200-959-7,CHEBI:7865,Numorphan,Morphinan-6-one,5-epoxy-3,14-dihydroxy-17-methyl-, (5.alpha.)-,Dihydro-14-hydroxymorphinone,Q423380,Oxymorphone 1.0 mg/ml in Methanol,(5alpha)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-6-one,14-Hydroxydihydromophone,Morphinan-6-one, 3,14-dihydroxy-4,5-alpha-epoxy-17-methyl-,NIH10323,C08019,Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5-alpha)-,4,5alpha-Epoxy-3,14-dihydroxy-17-methyl morphinan-6-one,DB01192,Dihydroxymorphinone,10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7,9,11(18)-trien-14-one,3,14-Dihydroxy-4,5-alpha-epoxy-17-methylmorphinan-6-one,Oxymorphone cii,Morphinan-6-one,5.alpha.-epoxy-3,14-dihydroxy-17-methyl-,Numorphone,Oxymorphone (INN),Morphinone, dihydro-14-hydroxy-,CHEMBL963,D08323,14-Hydroxydihydromorphinone,OXYMORPHONE [WHO-DD],(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one,DEA No. 9652,Oxymorphonum [INN-Latin],OXYMORPHONE [MI],4,5.alpha.-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one,SCHEMBL3571,DTXSID5023409,OXYMORPHONE [INN],opana,Oxymorphone,Oxymorphine,OXYCODONE HYDROCHLORIDE IMPURITY, OXYMORPHONE- [USP IMPURITY],NIH 10323,Oxymorphone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,Ossimorfone,OXYCODONE HYDROCHLORIDE IMPURITY A [EP IMPURITY],OXYMORPHONE CII [USP-RS],Oximorfona,MORPHINAN-6-ONE, 4,5-EPOXY-3,14-DIHYDROXY-17-METHYL-,OXYMORPHONE [VANDF],Oximorphonum,NSC19045,Oxymorphonum,HSDB 8060,Oxymorphone [INN:BAN],4,5-Epoxy-3,14-dihydroxy-N-methyl-6-oxomorphinan,Ossimorfone [DCIT],(5alpha)-4,5-Epoxy-3,14-dihydroxyl-17-methylmorphinan-6-one,GTPL7094,AKOS015962232,(-)-Oxymorphone,Morphinan-6-one, 4,5alpha-epoxy-3,14-dihydroxy-17-methyl- (8CI),(1S,5R,13R,17S)-10,17-dihydroxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one,Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)-,NSC 19045,Oxymorphone 0.1 mg/ml in Methanol,BRN 0041588,stopsigns,oxymorphone,Morphinan-6-one, 4,5alpha-epoxy-3,14-dihydroxy-17-methyl-,7,8-Dihydro-14-hydroxymorphinone,(14S)-14-Hydroxydihydromorphinone,(4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one,Oxycodone hydrochloride impurity, oxymorphone-,Morphinone, 7,8-dihydro-14-hydroxy- (6CI,7CI),NSC-19045, Oxymorphone (abuse-resistant, pain), Pain Therapeutics/Pfizer,Morphinan-6-one, 4,5-epoxy-3,14-dihydroxy-17-methyl-, (5alpha)- (9CI),10,17-dihydroxy-4-methyl-(13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one(xymorphone),Opana,HY-B0618,Dihydrohydroxymorphinone,Oxymorphone (abuse-resistant, pain),ZINC3875483,9VXA968E0C,IDS-NO-003,Oximorfona [INN-Spanish]

Estimated data

Solubilidad: -2.462 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 98.7% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.